Desktop Site
|
25 Apr 24 | 15:54
|
Open
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Get Quote
*
Notices
|
S&P
BSE SENSEX
74,339.44
+486.50
+0.66 %
Corporate Announcement
Security Code
524804
Company
Aurobindo Pharma Ltd
Exchange Received Time
06/05/2022 17:09:55
Exchange Disseminated Time
06/05/2022 17:09:55
Time Taken
00:00:00
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A |
05/06/22 17:09
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
Sr. No.
Particulars
Details
1
Name of Company
AUROBINDO PHARMA LTD.
2
CIN NO.
L24239TG1986PLC015190
3
Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)
0.00
4
Highest Credit Rating during the previous FY
0
4a
Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)
Not Applicable
5
Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework
BSE
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No
Name of the Company Secretary: MR B ADI REDDY
Designation: COMPANY SECRETARY
EmailId: cs@aurobindo.com
Name of the Chief Financial Officer: MR SANTHANAM SUBRAMANIAN
Designation: CHIEF FINANCIAL OFFICER
EmailId: subramanian.santhanam@aurobindo.com
Date: 06/05/2022
Note:
In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Attachment
<< Back
Recently Viewed